RA'ANANA, Israel, Dec. 16,
2024 /PRNewswire/ -- Inspira Technologies Oxy
B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies,"
"Inspira" or the "Company"), a groundbreaking respiratory
support technology company, announced the delivery of
INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med
Networks Inc ("Glo-Med"). The systems were shipped in fulfilment of
a purchase order issued by Glo-Med to Inspira.
The delivered INSPIRA™ ART100 systems will be distributed to
sales targets across hospitals on the U.S. east coast and
distributed to a cardiothoracic surgery division at a leading
New York
hospital, ranked among the top 15 percent of
cardiothoracic programs in the U.S., with a view to collaborating
with such hospital. The Company believes that the delivery of the
INSPIRA™ ART100 to the U.S. market serves the Company's goal
well to introduce physicians and perfusionists to Inspira's
technologies and brand via initial deployments at leading
hospitals.
Designed in collaboration with leading U.S. clinicians, the
INSPIRA™ ART100 cardiopulmonary bypass system revolutionizes
extracorporeal blood circulation by combining cutting-edge
technology with intuitive design to optimize patient care during
crucial times. The INSPIRA™ ART100 is planned to be integrated with
the HYLA™, a continuous blood monitoring technology designed to
potentially detect real-time changes in patient condition. The
HYLA™ is undergoing clinical evaluations at Sheba Hospital, ranked
the 9th in the world by Newsweek™, in patients
undergoing open-heart procedures, in preparation of the Company's
planned U.S. Food and Drug Administration ("FDA") submission of the
first configuration of the HYLA™ in 2025.
Dagi Ben-Noon, CEO of Inspira Technologies stated: "We
see this as merely the first deployment step in Inspira's quest to
revolutionize acute respiratory care with our groundbreaking
technology and superior products that we believe will follow this
initial distribution."
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to revolutionize
the $19 billion mechanical ventilation market. With 20
million intensive care unit patients with acute respiratory failure
each year, many of whom rely on mechanical ventilators, the INSPIRA
ART offers a potential alternative by elevating and stabilizing
decreasing oxygen saturation levels in minutes without a
ventilators, with patient being awake during treatment. The INSPIRA
ART is being equipped with the HYLA™ blood sensor technology, a
real-time continuous blood monitoring technology, aiming to alert
physicians of changes in a patient's condition without the need for
intermittent actual blood samples, and potentially supporting
physicians in making informed decisions.
The Company's INSPIRA™ ART100 system has obtained FDA
510(k) clearance for use in Cardiopulmonary Bypass procedures,
along with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen
Delivery System and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statements
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the prospective
distribution lines for the INSPIRA™ ART100 systems, the belief that
the delivery of the INSPIRA™ ART100 to the U.S. market serves the
Company's goal well to introduce physicians and perfusionists to
Inspira's technologies and brand via initial deployments at leading
hospitals, the benefits of the INSPIRA™ ART100 , its plan to
combine the INSPIRA™ ART100 with the HYLA™, the expected timing of
the planned FDA submission of the first configuration of the HYLA™,
and that its sees these distribution lines as the first deployment
step in Inspira's quest to revolutionize acute respiratory
care with its groundbreaking technology and superior products
that may follow. These forward-looking statements and their
implications are based solely on the current expectations of the
Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov.
Contact:
For more information, contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-technologies-delivers-systems-to-leading-distributor-for-us-deployment-302332518.html
SOURCE Inspira Technologies
